Nanobiotix SA

NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

05 Sep 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

31 Aug 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

15 Aug 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

04 Aug 2023 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

20 Jul 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

19 Jul 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

10 Jul 2023 01:00:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

08 Jun 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

17 May 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

05 May 2023 00:30:00 By Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

24 Apr 2023 18:33:54 By Nasdaq GlobeNewswire

NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

17 Apr 2023 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Apr 2023 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

27 Mar 2023 15:15:00 By Nasdaq GlobeNewswire

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

14 Mar 2023 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

14 Feb 2023 15:15:00 By Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 Jan 2023 15:15:00 By Nasdaq GlobeNewswire

NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

27 Dec 2022 00:45:00 By Nasdaq GlobeNewswire